Dihydroergocristine (mesylate)

Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1].

Product Specifications

CAS Number

[24730-10-7]

Product Name Alternative

DHEC (mesylate)

UNSPSC

12352005

Hazard Statement

H301, H312, H330, H410

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dihydroergocristine-mesylate.html

Purity

99.86

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C(C)C)C7=O)N7[C@H]2CC8=CC=CC=C8.CS(=O)(O)=O

Molecular Formula

C36H45N5O8S

Molecular Weight

707.84

Precautions

H301, H312, H330, H410

References & Citations

[1]Lei X, et al. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides. Sci Rep. 2015 Nov 16;5:16541.